This further underlines the importance of understanding the pathways by which PGC-1α exerts its effects on neuronal and whole-body function in ALS, and of validating the beneficial effects of modulating neuron-specific expression of the co-activator using other models of ALS. Here, PPARGC1A is linked to amyotrophic lateral sclerosis.